Phase-3 Randomized Controlled Trials on Exclusion of Participants With Kidney Disease in COVID-19-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase-3 Randomized Controlled Trials on Exclusion of Participants With Kidney Disease in COVID-19

Published:2021-01 Issue:1 Volume:6 Page:196-199
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Chewcharat Api,Chang Yuan-Ting,Sise Meghan E.,Bhattacharyya Roby P.,Murray Megan B.,Nigwekar Sagar U.

Funder

American Heart Association

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Elsevier BV

Subject

Nephrology

Reference9 articles.

1. Coronavirus disease 2019 (COVID-19): A literature review;Harapan;J Infect Public Health,2020

2. Acute kidney injury in patients hospitalized with COVID-19;Hirsch;Kidney Int,2020

3. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology;Batlle;J Am Soc Nephrol,2020

4. Update on the burden of CKD;Coresh;J Am Soc Nephrol,2017

5. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection;Henry;Int Urol Nephrol,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function;PLOS ONE;2023-02-27

2. COVID-19 Survival and its impact on chronic kidney disease;Translational Research;2022-03

3. Is There Enough Evidence to Avoid Remdesivir Use in Patients with Severe Renal Impairment? A Review of the Pharmacological and Clinical Literature;Mediterranean Journal of Infection Microbes and Antimicrobials;2021-12-12

4. A propensity-score matched observational study of remdesivir in patients with COVID-19 and severe kidney disease;Kidney360;2021-12-03

5. Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease;JAMA Network Open;2021-10-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3